^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)

i
Other names: BMPR1B, Bone Morphogenetic Protein Receptor Type 1B, CDw293, ALK6, Bone Morphogenetic Protein Receptor, Type IB, Bone Morphogenetic Protein Receptor Type-1B, BMP Type-1B Receptor, BMPR-1B, Serine/Threonine Receptor Kinase, Activin Receptor-Like Kinase 6, CDw293 Antigen, ALK-6, BDA1D, AMD3, AMDD, BDA2
Associations
Trials
2ms
Long noncoding RNA BMPR1B-DT promotes anoikis and reduces proliferation in ovarian cancer. (PubMed, BMC Cancer)
Our results suggest that BMPR1B-DT expression is critical in the process of anoikis in ovarian cancer patients. These insights underscore the necessity for further investigations aimed at translating these findings into clinical applications to improve diagnostic and therapeutic approaches for ovarian cancer patients.
Journal
|
BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
5ms
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma. (PubMed, Lung Cancer)
This comprehensive transcriptomic characterization of T-cell exclusion in PM reveals that targeting cilium-based Hedgehog signaling, in addition to multiple other actionable drug targets, could enhance the efficacy of ICB treatment in PM.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • SMO (Smoothened Frizzled Class Receptor) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) • KDM5B (Lysine Demethylase 5B) • SOX4 (SRY-Box Transcription Factor 4) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
5ms
Novel BMPR1B::AFF2 in a Sinonasal Region Non-Keratinizing Squamous Cell Carcinoma. (PubMed, Head Neck Pathol)
While the DEK::AFF2 fusion is well-characterized in sinonasal region tumors, alternate fusion partners are becoming increasingly recognized.
Journal
|
AFF2 (AF4/FMR2 family member 2) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
12ms
Atlas of genetic and phenotypic associations across 42 female reproductive health diagnoses. (PubMed, Nat Med)
We find that most female reproductive health diagnoses have a heritable component, with varying degrees of polygenicity and discoverability. Finally, we identify pleiotropic loci and genes that function in genital tract development (WNT4, PAX8, WT1, SALL1), hormonal regulation (FSHB, GREB1, BMPR1B, SYNE1/ESR1) and folliculogenesis (CHEK2), underlining their integral roles in female reproductive health.
Journal
|
ER (Estrogen receptor) • WT1 (WT1 Transcription Factor) • CHEK2 (Checkpoint kinase 2) • PAX8 (Paired box 8) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
1year
Fatty acid metabolism-related signature suggests an oncogenic role of TEKT1 in endometrial cancer. (PubMed, Taiwan J Obstet Gynecol)
A reliable predictive signature based on genes related to fatty acid metabolism in endometrial cancer was conducted, wherein TEKT1 was mainly implicated as the primary gene of interest. TEKT1 showed affinity to AMPK-γ and probably promoted FA synthesis in endometrial cancer.
Journal
|
GPX4 (Glutathione Peroxidase 4) • FASN (Fatty acid synthase) • ACACB (Acetyl-CoA Carboxylase Beta) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
over1year
Identification and validation of a prognostic model based on immune-related genes in ovarian carcinoma. (PubMed, PeerJ)
The analyses of genetic status of patients with 25-genes model might improve the ability to predict the prognosis of patients with OC and help to select patients suit able to therapies. Immune-related gene GBP1P1 might serve as prognostic biomarker for OC.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • GBP1 (Guanylate Binding Protein 1) • FZD3 (Frizzled Class Receptor 3) • MRPS11 (Mitochondrial Ribosomal Protein S11) • TNFAIP8 (TNF Alpha Induced Protein 8) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B) • KIF26B (Kinesin Family Member 26B)
over1year
Sponging of five tumour suppressor miRNAs by lncRNA-KCNQ1OT1 activates BMPR1A/BMPR1B-ACVR2A/ACVR2B signalling and promotes chemoresistance in hepatocellular carcinoma. (PubMed, Cell Death Discov)
Shrinkage of tumour size and volume in NOD-SCID mice injected with KCNQ1OT1-sgRNA cells further strengthened our observations. Thus, lncRNA-KCNQ1OT1 is the main regulator, which reduces the level of beneficiary miRNAs in the tumour milieu and modulates BMP signalling pathway to promote chemoresistance in HCC, suggesting lncRNA-KCNQ1OT1 might have robust potential to be a therapeutic target in HCC.
Journal
|
KCNQ1OT1 (KCNQ1 Opposite Strand/Antisense Transcript 1) • MIR139 (MicroRNA 139) • MIR223 (MicroRNA 223) • MIR375 (MicroRNA 375) • MIR424 (MicroRNA 424) • ACVR2A (Activin A Receptor Type 2A) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • MIR136 (MicroRNA 136) • ACVR2B (Activin A Receptor Type 2B) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
almost2years
Cell communication pathway prognostic model identified detrimental neurodevelopmental pathways in neuroblastoma. (PubMed, Neoplasia)
Notably, BMP7 expression was higher in neuroblastoma samples with distant metastases. In summary, CCPPM offers a novel approach to studying the influence of cell communication pathways on disease prognosis and identified detrimental communication pathways related to neurodevelopment.
Journal
|
ACVR2B (Activin A Receptor Type 2B) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
over2years
Overexpression of CD73 is associated with recurrence and poor prognosis of gingivobuccal oral cancer as revealed by transcriptome and deep immune profiling of paired tumor and margin tissues. (PubMed, Cancer Med)
High infiltration of anti-tumor immune cells in both tumors and margins results in good prognosis, while in patients with minimal infiltration in tumors in spite of high infiltration in margins results in poor prognosis. Targeted CD73 immune-checkpoint inhibition may improve clinical outcome.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NT5E (5'-Nucleotidase Ecto) • TLR4 (Toll Like Receptor 4) • ITGA6 (Integrin, alpha 6) • RBP1 (Retinol Binding Protein 1) • THRA (Thyroid Hormone Receptor Alpha) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
|
CD73 overexpression • CD73 expression • NT5E overexpression
over2years
Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors. (PubMed, Breast Cancer Res)
Our work identified a unique tumorigenic microenvironment of the interface zone and allowed for deeper insights into the tumor microenvironment of breast cancer that will serve as a helpful resource for advancing breast cancer diagnosis and therapy.
Journal
|
BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
over2years
Bioinformatics Analysis of the Genetic and Epigenetic Alterations of Bone Morphogenetic Protein Receptors in Metastatic Breast Cancer. (PubMed, Biochem Genet)
BMPR1B, BMPR2, and ACVR2A levels were significantly linked as moderate prediction of anti-HER2, BMPR2, and ACVR1B demonstrated moderate predictive potential for chemotherapy sensitivity. This study contributed in fully comprehending the significance of genetic and epigenetic alterations in BMP receptors and BMP signaling in metastatic breast cancer cells for the development of breast cancer treatment plans.
Review • Journal • Metastases
|
ACVR1 (Activin A Receptor Type 1) • ACVR2A (Activin A Receptor Type 2A) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • ACVR1B (Activin A Receptor Type 1B) • ACVR2B (Activin A Receptor Type 2B) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)